20.72
0.67 (3.34%)
| Previous Close | 20.05 |
| Open | 20.23 |
| Volume | 1,991,899 |
| Avg. Volume (3M) | 1,781,218 |
| Market Cap | 2,484,433,152 |
| Price / Earnings (Forward) | 263.16 |
| Price / Sales | 10.13 |
| Price / Book | 18.33 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | -60.95% |
| Operating Margin (TTM) | -37.25% |
| Diluted EPS (TTM) | -1.04 |
| Quarterly Revenue Growth (YOY) | 32.80% |
| Total Debt/Equity (MRQ) | 77.67% |
| Current Ratio (MRQ) | 3.55 |
| Operating Cash Flow (TTM) | -110.94 M |
| Levered Free Cash Flow (TTM) | -66.54 M |
| Return on Assets (TTM) | -18.43% |
| Return on Equity (TTM) | -70.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arcutis Biotherapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | -4.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -1.30 |
|
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.95% |
| % Held by Institutions | 108.79% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Suvretta Capital Management, Llc | 30 Jun 2025 | 11,535,582 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (Needham, 6.18%) | Buy |
| Median | 20.00 (-3.48%) | |
| Low | 18.00 (Goldman Sachs, -13.13%) | Hold |
| Average | 20.00 (-3.48%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 14.49 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 07 Aug 2025 | 22.00 (6.18%) | Buy | 14.12 |
| Goldman Sachs | 25 Jul 2025 | 18.00 (-13.13%) | Hold | 14.86 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| EDWARDS LARRY TODD | - | 21.25 | -4,504 | -95,710 |
| WATANABE TODD | - | 20.51 | -45,000 | -920,101 |
| WELGUS HOWARD G. | - | 19.76 | -10,000 | -197,600 |
| Aggregate Net Quantity | -59,504 | |||
| Aggregate Net Value ($) | -1,213,411 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 20.51 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WATANABE TODD | Officer | 02 Oct 2025 | Automatic sell (-) | 20,739 | 21.25 | 440,704 |
| EDWARDS LARRY TODD | Officer | 02 Oct 2025 | Sell (-) | 4,504 | 21.25 | 95,710 |
| WELGUS HOWARD G. | Director | 01 Oct 2025 | Automatic sell (-) | 10,000 | 19.76 | 197,600 |
| WELGUS HOWARD G. | Director | 01 Oct 2025 | Option execute | 9,538 | - | - |
| WATANABE TODD | Officer | 01 Oct 2025 | Automatic sell (-) | 24,261 | 19.76 | 479,397 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |